# Shigella Sonnei 53G Human Infection Study in Kenyan Adults

> **NCT05959616** · PHASE1 · RECRUITING · sponsor: **University of Oxford** · enrollment: 70 (estimated)

## Conditions studied

- Shigellosis

## Interventions

- **BIOLOGICAL:** Shigella sonnei 53G
- **DRUG:** Ciprofloxacin 500 mg

## Key facts

- **NCT ID:** NCT05959616
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-21
- **Primary completion:** 2026-04-30
- **Final completion:** 2027-08-30
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-03-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05959616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05959616, "Shigella Sonnei 53G Human Infection Study in Kenyan Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05959616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*